Zomedica Corp. (ZOM) News
Filter ZOM News Items
ZOM News Results
|Loading, please wait...|
ZOM News Highlights
- 500 - Internal server error
- Over the past 13 days, the trend for ZOM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- NIO are the most mentioned tickers in articles about ZOM.
Latest ZOM News From Around the Web
Below are the latest news stories about Zomedica Corp that investors may wish to consider to help them evaluate ZOM as an investment opportunity.
Zomedica came public too soon, but it does have enough cash to see a finish line.
ZOM stock has come under price pressure recently, but the outlook is bright as Zomedica plots a road map to success.
It's not there yet, but if ZOM stock pulls back another 50% or so, the risk/return proposition will be more in your favor.
Two of the assays used by Zomedica’s Truforma platform aren’t yet available.
ZOM stock is rife with massive potential.
These penny stocks are trading at cheap valuations, but they also have the potential to make major waves this year.
As one of the newer plays in the market, WOOF stock generated significant attention but understand the risks before diving in.
ZOM stock is trading below $1 as investors are in a holding pattern as they wait for the company to report earnings in August.
FOCUSED ON TRUFORMA® INSTRUMENT PLACEMENTS AND BUILDING DIRECT SALES ORGANIZATION ANN ARBOR, Mich., July 06, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, provided the following corporate update: As previously announced, Zomedica’s flagship product – TRUFORMA® – is intended to have five initial assays to test for adrenal and thyroid disorders, which will be fol
With the "story" behind it still years in the making, take your time with BNGO stock.